Literature DB >> 15001472

Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation.

Roland Meisel1, Andree Zibert, Maurice Laryea, Ulrich Göbel, Walter Däubener, Dagmar Dilloo.   

Abstract

Marrow stromal cells (MSCs) inhibit allogeneic T-cell responses, yet the molecular mechanism mediating this immunosuppressive effect of MSCs remains controversial. Recently, expression of indoleamine 2,3-dioxygenase (IDO), which is induced by interferon-gamma (IFN-gamma) and catalyzes the conversion from tryptophan to kynurenine, has been identified as a T-cell inhibitory effector pathway in professional antigen-presenting cells. Here we show that human MSCs express IDO protein and exhibit functional IDO activity upon stimulation with IFN-gamma. MSCs inhibit allogeneic T-cell responses in mixed lymphocyte reactions (MLRs). Concomitantly, IDO activity resulting in tryptophan depletion and kynurenine production is detected in MSC/MLR coculture supernatants. Addition of tryptophan significantly restores allogeneic T-cell proliferation, thus identifying IDO-mediated tryptophan catabolism as a novel T-cell inhibitory effector mechanism in human MSCs. As IDO-mediated T-cell inhibition depends on MSC activation, modulation of IDO activity might alter the immunosuppressive properties of MSCs in different therapeutic applications.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15001472     DOI: 10.1182/blood-2003-11-3909

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  572 in total

1.  Immune modulation of co-transplantation mesenchymal stem cells with islet on T and dendritic cells.

Authors:  F R Li; X G Wang; C Y Deng; H Qi; L L Ren; H X Zhou
Journal:  Clin Exp Immunol       Date:  2010-05-07       Impact factor: 4.330

2.  Allogeneic mesenchymal stem cells do not protect NZBxNZW F1 mice from developing lupus disease.

Authors:  M Youd; C Blickarz; L Woodworth; T Touzjian; A Edling; J Tedstone; M Ruzek; R Tubo; J Kaplan; T Lodie
Journal:  Clin Exp Immunol       Date:  2010-04-29       Impact factor: 4.330

3.  Multipotent Mesenchymal Stromal Cells for Autoimmune Diseases.

Authors:  Alan Tyndall
Journal:  Transfus Med Hemother       Date:  2008-07-17       Impact factor: 3.747

Review 4.  Mesenchymal stromal cells for cell therapy: besides supporting hematopoiesis.

Authors:  Lei Hao; Huiqin Sun; Jin Wang; Tao Wang; Mingke Wang; Zhongmin Zou
Journal:  Int J Hematol       Date:  2011-12-20       Impact factor: 2.490

5.  Emerging roles for multipotent, bone marrow-derived stromal cells in host defense.

Authors:  Jeffery J Auletta; Robert J Deans; Amelia M Bartholomew
Journal:  Blood       Date:  2012-01-06       Impact factor: 22.113

6.  Inflammatory conditions affect gene expression and function of human adipose tissue-derived mesenchymal stem cells.

Authors:  M J Crop; C C Baan; S S Korevaar; J N M Ijzermans; M Pescatori; A P Stubbs; W F J van Ijcken; M H Dahlke; E Eggenhofer; W Weimar; M J Hoogduijn
Journal:  Clin Exp Immunol       Date:  2010-09-15       Impact factor: 4.330

Review 7.  Mesenchymal stem cells: Mechanisms of immunomodulation and homing.

Authors:  Hiroshi Yagi; Alejandro Soto-Gutierrez; Biju Parekkadan; Yuko Kitagawa; Ronald G Tompkins; Naoya Kobayashi; Martin L Yarmush
Journal:  Cell Transplant       Date:  2010-06-03       Impact factor: 4.064

8.  Kynurenine, a Tryptophan Metabolite That Accumulates With Age, Induces Bone Loss.

Authors:  Mona El Refaey; Meghan E McGee-Lawrence; Sadanand Fulzele; Eileen J Kennedy; Wendy B Bollag; Mohammed Elsalanty; Qing Zhong; Ke-Hong Ding; Nathaniel G Bendzunas; Xing-Ming Shi; Jianrui Xu; William D Hill; Maribeth H Johnson; Monte Hunter; Jessica L Pierce; Kanglun Yu; Mark W Hamrick; Carlos M Isales
Journal:  J Bone Miner Res       Date:  2017-08-14       Impact factor: 6.741

9.  Induced pluripotent stem cells have similar immunogenic and more potent immunomodulatory properties compared with bone marrow-derived stromal cells in vitro.

Authors:  Lauren V Schnabel; Christian M Abratte; John C Schimenti; M Julia Bevilaqua Felippe; Jennifer M Cassano; Teresa L Southard; Jessica A Cross; Lisa A Fortier
Journal:  Regen Med       Date:  2014-04-28       Impact factor: 3.806

Review 10.  Immune regulatory cell infusion for graft-versus-host disease prevention and therapy.

Authors:  Bruce R Blazar; Kelli P A MacDonald; Geoffrey R Hill
Journal:  Blood       Date:  2018-05-04       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.